دورية أكاديمية
Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID.
| العنوان: | Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID. |
|---|---|
| المؤلفون: | Uzzan, Mathieu, Nachury, Maria, Nuzzo, Alexandre, Amiot, Aurélien, Caron, Bénédicte, Benezech, Alban, Buisson, Anthony, Bouguen, Guillaume, Le Berre, Catherine, Reenaers, Catherine, Le Cosquer, Guillaume, Savoye, Guillaume, Charkaoui, Maeva, Vidon, Mathias, Guillo, Lucas, Fumery, Mathurin, Peyrin-Biroulet, Laurent, Kirchgesner, Julien, Bouhnik, Yoram, GETAID TOFA-PRO study |
| المصدر: | Journal of Crohn's and Colitis (2024) |
| بيانات النشر: | Oxford University Press, 2024. |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Ulcerative proctitis, refractory proctitis, tofacitinib, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie |
| الوصف: | BACKGROUND: While ulcerative proctitis (UP) can dramatically impair quality-of-life, treatments efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomized controlled trials in ulcerative colitis. AIM: To assess the effectiveness and safety of tofacitinib for the treatment of UP. METHODS: We conducted a retrospective multicenter study in seventeen GETAID centers including consecutive patients with UP treated with tofacitinib. The primary endpoint was steroid-free remission between week 8 and week 14, defined as a partial Mayo score of 2 (and no individual subscore above 1). Secondary outcomes included clinical response and steroid-free remission after induction and at one year. RESULTS: All the 35 enrolled patients previously received anti-TNF therapy and 88.6% were exposed to at least two lines of biologics. At baseline, the median partial Mayo score was 7 (IQR[5.5-7]). After induction (W8-W14), 42.9% and 60.0% of patients achieved steroid-free remission and clinical response, respectively. At one year, the steroid-free clinical remission and clinical response rates were 39.4% and 45.5%, respectively, while 51.2% (17/33) were still receiving tofacitinib treatment. Survival without tofacitinib withdrawal was estimated at 50.4% (95%CI[35.5-71.6]) at one year. Only a lower partial Mayo at baseline was independently associated with remission at induction (Odds ratio (OR) = 0.56 for an increase of 1, 95% confidence interval (95%CI) [0.33-0.95], p = 0.03). Five (14.3%) adverse events were reported with one leading to treatment withdrawal (septic shock secondary to cholecystitis). CONCLUSION: Tofacitinib may offer a therapeutic option for patients with refractory UP. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article peer reviewed |
| اللغة: | English |
| Relation: | https://doi.org/10.1093/ecco-jcc/jjad169; 10.1093/ecco-jcc/jjad169; urn:issn:1873-9946; urn:issn:1876-4479 |
| DOI: | 10.1093/ecco-jcc/jjad169 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/311919 |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الأكسشن: | edsorb.311919 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1093/ecco-jcc/jjad169 |
|---|